Lurbinectedin is a drug that is currently used in the treatment of small cell lung cancer (SCLC). According to a study published in Frontiers in Oncology [3], lurbinectedin has shown promising results in combination with immunotherapy in the treatment of SCLC. The study reported that the combination of lurbinectedin and immunotherapy improved the response rate and overall survival in patients with SCLC.

Another study published in OncLive [2] reported that the combination of chemotherapy and immunotherapy regimens have improved long-term outcomes in patients with SCLC. The study concluded that the combination of chemotherapy and immunotherapy may be an effective treatment option for patients with SCLC.

However, there is no direct evidence available to suggest that lurbinectedin can improve long-term immunotherapy outcomes. The drug patent watch [1] provides information about the drug and its current uses but does not provide any information about its potential to improve long-term immunotherapy outcomes.

In conclusion, while there is evidence to suggest that lurbinectedin in combination with immunotherapy can improve the response rate and overall survival in patients with SCLC, there is no direct evidence available to suggest that it can improve long-term immunotherapy outcomes. Further research is needed to explore the potential benefits of lurbinectedin in combination with immunotherapy in the treatment of SCLC.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.onclive.com/view/chemoimmunotherapy-regimens-improve-long-term-outcomes-in-small-cell-lung-cancer
[3] https://www.frontiersin.org/articles/10.3389/fonc.2023.1142081/full